シンバイオ製薬(株)【4582】の掲示板 2020/07/16〜2020/07/28

Wall Street hails Chimerix viral load; COVID-19, smallpox bids forge onward
April 29, 2020 By Randy Osborne No Comments
A pair of good-news items from Chimerix Inc. pushed the Durham, N.C.-based company’s stock (NASDAQ:CMRX) to $2.15, closing up 64 cents, or 42%, higher as backers reacted to near-term NDA plans for smallpox countermeasure brincidofovir (BCV) and the start of a phase II/III trial with dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI).

4月の記事です。シンバイオは、ブリンシドフォビルの天然痘以外の全ての疾患領域において、グローバルの独占権利を保有しているとの事ですが、pandemicのコロナは？どうなんでしょうか^ - ^